The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or uUTIs, successfully and safely.

If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...

The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be available in the second half of 2025. Blujepa is approved to treat females 12 and older with uncomplicated ...

The drug chemically known as gepotidacin is designed to target the most common UTI-causing bacteria such as E. coli, the company said. The drug acts on a different part of the bacteria compared to ...

Gepotidacin is the first new class of oral antibiotics for uUTIs in nearly 30 years, addressing rising drug resistance. Phase 3 trials showed gepotidacin's non-inferiority to nitrofurantoin ...

Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

GSK has unveiled the data for its novel antibiotic gepotidacin as a treatment for gonorrhoea, putting the drug on track to become an important therapy for people with resistant forms of the ...

Please provide your email address to receive an email when new articles are posted on . Gepotidacin is the first in a new class of oral antibiotics for uUTIs in nearly 30 years. The approval was ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes. Study participants were ...